About the Test for Oncology

Providing answers you need at the speed patients deserve

With the rise of precision oncology, genomic profiling is playing a larger role in clinical decision making, helping bring clarity to targeted treatment approaches. Across all advanced cancer types, the Oncotype MAP Pan-Cancer Tissue test can help when you need faster answers.

Explore the benefits of the Oncotype MAP test

Fast, actionable insights help bring clarity to treatment options

Oncotype MAP packaging The Oncotype MAP test delivers rapid, comprehensive tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. The test identifies actionable genomic alterations within 3-5 business days*† to help guide timely treatment decisions, usually before the next follow up visit.

Using next generation sequencing (NGS) and a broad array of immunohistochemical (IHC) stains and panels, the test identifies clinically-relevant genomic alterations from patient specimens as small as 3 mm2 of tissue with ≥15% tumor content*, about the size of a grain of rice. Fewer Quantity Not Sufficient (QNS) samples mean more of your patients get tested and treated.

Why choose the Oncotype MAP Pan-Cancer Tissue test?

The Oncotype MAP test can provide in-depth insights into alterations of hundreds of cancer-related genes, usually before the patient’s next follow-up visit.
icon comprehensive

Comprehensive

  • 257 genes (SNVs, CNVs, fusions & structural variants).
  • IO signatures including tumor mutational burden (TMB) and microsatellite instability (MSI).
  • 24 Immunohistochemistry (IHC) stains including PD-L1 (SP142, 22C3).
  • icon fast

    Fast Turnaround Time

  • Results reported in 3-5 business days.*†
  • Quantity not sufficient (QNS) results reported in as few as 2 business days.*
  • icon actionable

    Accurate

  • >99% sensitivity and specificity,‡ even on samples as small as 3 mm2.
  • icon accurate

    Actionable

  • 100+ therapies.
  • 45+ combination therapies.
  • 650+ clinical trials.
  • Oncotype MAP Pan-Cancer Tissue test markers

    VIEW 257 GENE NGS PANEL
    257 Gene NGS Panel
    ABCB1
    ABCC1
    ABCC2
    ABL1
    ACVR1
    ACVR1B
    ACVR2A
    ACVR2B
    ACVRL1
    ADAMTS1
    ADAMTS6
    ADAMTS9
    ADAMTS16
    ADAMTS18
    ADAMTSL1
    AKT1
    AKT2
    AKT3
    ALK
    AMER1
    APC
    APLNR
    AR
    ARAF
    AREG
    ARID1A
    ARID1B
    ARID2
    ATM
    ATR
    ATRX
    AURKA
    AURKB
    AXIN1
    AXL
    B2M
    BAP1
    BARD1
    BCOR
    BMP6
    BMPR1A
    BMPR1B
    BNIP3
    BRAF
    BRCA1
    BRCA2
    BRIP1
    BTK
    BUB1B
    CALR
    CBL
    CCND1
    CCND2
    CCND3
    CCNE1
    CD274
    CDA
    CDC73
    CDH1
    CDK4
    CDK6
    CDK12
    CDKN2A
    CHEK1
    CHEK2
    CHFR
    CHKA
    CIC
    CREBBP
    CSF1R
    CTLA4
    CTNNB1
    CYP19A1
    CYP1A1
    CYP2D6
    CYP3A4
    CYSLTR2
    DCK
    DDR2
    DICER1
    DNMT3A
    EGFR
    EMSY
    EP300
    EPCAM
    EPHA5
    EPHA7
    ERBB2
    ERBB3
    ERBB4
    ERCC1
    ERCC2
    ERCC3
    ERRFI1
    ESR1
    ESR2
    EWSR1
    EZH2
    FAM175A
    FANCA
    FANCC
    FANCD2
    FANCE
    FANCF
    FANCG
    FANCM
    FAT1
    FBXW7
    FCGR2A
    FGD4
    FGF3
    FGF4
    FGFR1
    FGFR2
    FGFR3

    FGFR4
    FLT3
    FLT4
    FOXL2
    FUBP1
    GAS6
    GATA3
    GLI1
    GNA11
    GNAQ
    GNAS
    GSTP1
    HAMP
    HDAC2
    HGF
    HNF1A
    HRAS
    HSD3B1
    IDH1
    IDH2
    IGF1R
    IKZF1
    IL6R
    JAK1
    JAK2
    JAK3
    KDM5C
    KDM6A
    KDR
    KEAP1
    KIT
    KRAS
    MAF
    MAP2K1
    MAP2K2
    MAP3K1
    MAPK1
    MAPK3
    MAPKAPK5
    MDM2
    MDM4
    MED12
    MEN1
    MET
    MGMT
    MLH1
    MPL
    MRE11A
    MSH2
    MSH6
    MTHFR
    MTOR
    MUTYH
    MYC
    MYCN
    MYOD1
    NBN
    NF1
    NF2
    NFE2L2
    NOTCH1
    NOTCH2
    NOTCH3
    NPMI
    NRAS
    NTRK1
    NTRK2
    NTRK3

    PALB2
    PBRM1
    PDCD1LG2
    PDGFRA
    PDGFRB
    PIK3CA
    PIK3CB
    PIK3CD
    PIK3CG
    PIK3R1
    PIM1
    PLCB4
    PLCG1
    PMS2
    POLD1
    POLE
    PP2R1A
    PTCH1
    PTEN
    PTPN11
    RAD50
    RAD51C
    RAD51D
    RAF1
    RB1
    RBM10
    RECQL
    RET
    RHEB
    RICTOR
    RIT1
    RNF43
    ROS1
    RPTOR
    RRMI
    SDHB
    SDHC
    SETD2
    SF3B1
    SMAD1
    SMAD2
    SMAD4
    SMAD5
    SMAD9
    SMARCA4
    SMARCB1
    SMO
    SOCS1
    SPOP
    STAG2
    STAT3
    STAT5A
    STAT5B
    STK11
    SUFU
    TERT-p
    TGFB1
    TGFB2
    TGFB2
    TGFB3
    TGFBR1
    TGFBR2
    TNFA1P3
    TNK1
    TOP2A
    TP53
    TSC1
    TSC2
    TSHR
    TYMS
    VEGFA
    VHL
    WTI
    XRCC1
    YES1
    Bolded genes include fusions.
    VIEW SINGLE IHC STAINS -and- TUMOR-SPECIFIC IHC PANELS
    Single IHC Stains
    *MMR Panel
    ALK
    AR
    CAIX
    ER
    hENTI
    HER2
    IDO
    MET
    MGMT
    PD1
    PD-L1 (22C3)
    PD-L1 (SP142)
    PR
    PTEN
    ROS1
    TOP1
    TP
    TRKpan
    TS
    TUBB3
    MLH1
    MSH2
    MSH6
    PMS2
    Tumor-Specific Panels
    Anal: PD-L1 (22C3), MMR*
    Appendix: HER2, PTEN, MMR*
    Bladder: PD-L1 (22C3), PD-L1 (SP142), MMR*
    Breast: AR, PD-L1 (22C3), MMR*
      Previously tested for HER2/ER/PR.
      Otherwise HER2, ER, PR, PD-L1 (22C3), MSH6, PMS2.
    Cervical: PD-L1 (22C3), ER, MMR*
    Cholanglocarinoma: HER2, PD-L1 (22C3), MMR*
    CNS/Brain: MGMT, CAIX, MMR*
    Colorectal: HER2, PTEN, MMR*
    Esophagus: HER2, PD-L1 (22C3), MMR*
    Gallbladder: HER2, PD-L1 (22C3), ER, MMR*
    Gastric: HER2, PD-L1 (22C3), MMR*
    Head and Neck, Salivary Gland: HER2, AR, MMR*
    Head and Neck, Squamous: PD-L1 (22C3), TUBB3, MMR*
    Hepatocellular: HER2, PD-L1 (22C3), MMR*
    Kidney: PD-L1 (22C3), MET, MMR*
    Melanoma: PD-L1 (22C3), PTEN, MMR*
    Mesothelioma: PD-L1 (22C3), TS, MMR*
    Neuroendocrine: PD-L1 (22C3), PTEN, MMR*
    NSCLC: PD-L1 (22C3), PD-L1 (SP142), ALK, MSH6, PMS2
    Ovarian: ER, HER2, MMR*
    Pancreatic: MMR*, PTEN, hENT1
    Penile Cancer: PD-L1 (22C3), MMR*
    Prostate: AR, PD-L1 (22C3), MMR*
    Skin, Non-melanoma: PD-L1 (22C3), MMR*
    Small Bowel: HER2, PTEN, MMR*
    Soft Tissue: MMR*
    Testicular: PD-L1 (22C3), MMR*
    Thymus: PD-L1 (22C3), TUBB3, MMR*
    Thyroid: PD-L1 (22C3), ALK, MMR*
    Uterine: ER, HER2, MMR*
    Vulvar: PD-L1 (22C3), ER, MMR*
    Other Solid Tumors: PD-L1 (22C3), HER2, MMR*

    Interpreting the report

    Results are provided in an easy-to-interpret report which links actionable biomarkers to current therapy guidelines to help guide treatment options. The report also includes potential evidence-based therapies and clinical trials, delivering treatment options for a breadth of solid tumor types.

    REFERENCES

    *Data on File.
    † Turnaround time is based on qualified sample receipt.
    ‡ >99% sensitivity for small variants (substitutions, insertions, and deletions). Detection down to ≥7.5% mutant allele frequency (MAF) with >99% specificity. Data on file.

    Making cancer care smarter.™